| Acute lymphocytic leukemia
Asparlas vs Rituxan
Side-by-side clinical, coverage, and cost comparison for acute lymphocytic leukemia.Deep comparison between: Asparlas vs Rituxan with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRituxan has a higher rate of injection site reactions vs Asparlas based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rituxan but not Asparlas, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Asparlas
Rituxan
At A Glance
IV infusion
Every 21 days
Pegylated L-asparaginase
IV infusion
Anti-CD20 monoclonal antibody
Indications
- Acute lymphocytic leukemia
- Lymphoma, Non-Hodgkin
- Chronic Lymphocytic Leukemia
- Rheumatoid Arthritis
- Granulomatosis with polyangiitis
- Microscopic Polyarteritis
- Pemphigus Vulgaris
- Acute lymphocytic leukemia
Dosing
Acute lymphocytic leukemia 2,500 units/m2 intravenously no more frequently than every 21 days.
Lymphoma, Non-Hodgkin 375 mg/m2 IV; weekly for 4 or 8 doses for relapsed/refractory low-grade or follicular NHL; Day 1 of each chemotherapy cycle for up to 8 doses for previously untreated follicular or DLBCL; every 8 weeks for 12 doses as single-agent maintenance.
Acute lymphocytic leukemia 375 mg/m2 IV for 6 total infusions in combination with LMB chemotherapy (two doses during each of the two induction courses, one dose during each of the two consolidation courses) for pediatric patients aged 6 months and older.
Chronic Lymphocytic Leukemia 375 mg/m2 IV the day prior to initiation of cycle 1 FC chemotherapy, then 500 mg/m2 on Day 1 of cycles 2-6 every 28 days.
Rheumatoid Arthritis Two 1,000 mg IV infusions separated by 2 weeks per course in combination with methotrexate; subsequent courses every 24 weeks (no sooner than 16 weeks); premedicate with methylprednisolone 100 mg IV 30 minutes prior to each infusion.
Granulomatosis with polyangiitis, Microscopic Polyarteritis Induction: 375 mg/m2 IV once weekly for 4 weeks with glucocorticoids; follow-up: two 500 mg IV infusions separated by 2 weeks, then 500 mg IV every 6 months based on clinical evaluation.
Pemphigus Vulgaris Two 1,000 mg IV infusions separated by 2 weeks in combination with a tapering course of glucocorticoids; then 500 mg IV at Month 12 and every 6 months thereafter or based on clinical evaluation.
Contraindications
- History of serious hypersensitivity reactions, including anaphylaxis, to pegylated L-asparaginase therapy
- History of serious pancreatitis during previous L-asparaginase therapy
- History of serious thrombosis during previous L-asparaginase therapy
- History of serious hemorrhagic events during previous L-asparaginase therapy
- Severe hepatic impairment
—
Adverse Reactions
Most common Elevated transaminase, bilirubin increased, pancreatitis, abnormal clotting studies, diarrhea, hypersensitivity, embolic and thrombotic events, sepsis, dyspnea, hemorrhages, fungal infection, pneumonia, arrhythmia, cardiac failure
Serious Hypersensitivity, pancreatitis, thrombosis, hemorrhage, hepatotoxicity including veno-occlusive disease
Postmarketing Veno-occlusive disease (hepatic)
Most common (>=25%) Infusion-related reactions, fever, lymphopenia, chills, infection, asthenia (in NHL); infusion-related reactions, neutropenia (in CLL)
Serious Fatal infusion-related reactions, severe mucocutaneous reactions, hepatitis B reactivation with fulminant hepatitis, progressive multifocal leukoencephalopathy, tumor lysis syndrome, sepsis, cardiovascular events, renal toxicity, bowel obstruction and perforation
Postmarketing Prolonged pancytopenia, fatal cardiac failure, progressive multifocal leukoencephalopathy, severe mucocutaneous reactions, pyoderma gangrenosum, bowel obstruction and perforation, fatal bronchiolitis obliterans, fatal interstitial lung disease, posterior reversible encephalopathy syndrome
Pharmacology
Pegylated L-asparaginase enzyme that depletes plasma asparagine by catalyzing its conversion to aspartic acid and ammonia; leukemic cells with low asparagine synthetase expression depend on exogenous asparagine for survival and are killed by its depletion.
Rituximab is a chimeric murine/human IgG1 kappa monoclonal antibody that binds the CD20 antigen on pre-B and mature B-lymphocytes, mediating B-cell lysis via complement dependent cytotoxicity (CDC) and antibody dependent cell mediated cytotoxicity (ADCC).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Asparlas
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
Rituxan
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
UnitedHealthcare
Asparlas
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Rituxan
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Asparlas
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Rituxan
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Asparlas Patient Assistance ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Rituxan.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AsparlasView full Asparlas profile
RituxanView full Rituxan profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.